Astera Labs (Astera Labs (ALAB)) shares bounced back on Tuesday after TD Cowen raised its price forecast on the stock to $425 while keeping a Hold rating. The move came as the broader market rallied, with the Nasdaq up 1.36% and the S&P 500 adding 0.39%.
The price target bump is the latest in a string of good news for the fabless chip company, which has seen its stock surge 120.51% year to date. But Tuesday's gain was really about recovery—Monday was a rough day for chip stocks, and Astera Labs got caught in the downdraft.
What Hit Astera Labs on Monday?
Monday's selloff in semiconductor stocks had a distinctly global flavor. Weakness started in South Korea, where declines in Samsung Electronics and SK Hynix dragged down the KOSPI index and spilled over to U.S. peers. On top of that, rising energy costs after military exchanges between the U.S. and Iran, plus comments from President Donald Trump, added to the market's jitters.
But Astera Labs had some company-specific headwinds too. The stock saw profit-taking after its June 22 inclusion in the Nasdaq-100, which triggered index rebalancing adjustments. And SEC filings revealed that Board Chairman Manuel Alba and Director Stefan Dyckerhoff executed multi-million dollar automated stock sales under Rule 10b5-1 trading plans. Insider selling always catches traders' attention, even when it's pre-planned.
Earnings on the Horizon
With the noise from Monday fading, traders are now looking ahead to Astera Labs' second-quarter earnings, scheduled for August 4. Analysts are expecting earnings per share of 64 cents and quarterly revenue of $360.21 million. Those numbers will be a big test for a stock that's already run up so much this year.
What the Charts Say
Technically, Astera Labs is in a mixed spot. The stock is trading 7.3% below its 20-day moving average of $406.14, which suggests some near-term weakness. But it's still 13.4% above its 50-day SMA of $332.10, so the intermediate trend looks intact. And the longer-term picture is firmly bullish: the stock is 59.7% above its 100-day SMA and 87% above its 200-day SMA.
The Relative Strength Index (RSI) sits at 49.21, which is right around neutral. That's a big shift from June, when the stock was overbought. So the cooling-off period may be giving the stock room to run again—or it could be a sign that momentum is fading.
Price Action
As of Tuesday's publication, Astera Labs shares were up 2.91% at $372.58. The stock has had a wild ride this year, and with earnings coming up, the next few weeks could be pivotal.
.jpeg)
